What do systematic reviews say?

Intervention not reported

It is very uncertain whether the intervention changes time to pregnancy (very low certainty).

• Timed intercourse for couples trying to conceive 2023 · Cochrane Headline outcomes only
  OR 1.77 [0.1, 3.2]
  2 studies · 2 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes clinical pregnancy rate (very low certainty).

• Timed intercourse for couples trying to conceive 2023 · Cochrane Headline outcomes only
  RR 1.13 [0.31, 4.07]
  1 study · 17 participants
  Very low

NSAIDs vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NSAIDs vs paracetamol

It is very uncertain whether NSAIDs changes delayed antibiotic prescriptions compared with paracetamol (very low certainty).

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  RR 1.32 [0.74, 2.35]
  1 study · 53 participants
  Very low

Paracetamol vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intensity of glycaemic control for women with gestational diabetes mellitus ‐ strict glycaemic targets vs less‐tight glycaemic targets (maternal outcomes)

The review found no eligible studies for this question.

• Different intensities of glycaemic control for women with gestational diabetes mellitus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 142 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs vitamin C

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 170 participants
  Very low

Intervention not reported

The intervention may leads to higher breast cancer stage at the time of presentation: defined as the… (low certainty).

• Training health workers in clinical breast examination for early detection of breast cancer in low‐ and middle‐income… 2023 · Cochrane Headline outcomes only
  RR 1.44 [1.01, 2.06]
  3 studies · 593 participants
  Low

Intervention not reported

The intervention may leads to lower breast cancer stage at the time of presentation: defined as the… (low certainty).

• Training health workers in clinical breast examination for early detection of breast cancer in low‐ and middle‐income… 2023 · Cochrane Headline outcomes only
  RR 0.58 [0.36, 0.94]
  3 studies · 593 participants
  Low

Intervention not reported

• Training health workers in clinical breast examination for early detection of breast cancer in low‐ and middle‐income… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Very low

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 5 participants
  Very low

Alglucosidase alfa vs placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Moderate

VAL‐1221 vs alglucosidase alfa

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 133 participants
  Moderate

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Low

Avalglucosidase alfa vs alglucosidase alfa

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Moderate

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Telemedicine vs usual care

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low